- Price
- $26.44
- Day
- +4.26%
- Mkt Cap
- $420.21M
- 52W Range
- $18.41 – $39.71
- Volume
- 88.6K
- Beta
- 1.09
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Assembly Biosciences has evolved into a strategically financed antiviral platform, underpinned by a robust partnership with Gilead and a strengthened balance sheet. ASMB's pipeline targets high-unmet-need indications—recurrent genital herpes, HDV, and cholestatic liver diseases—with differentiated mechanisms and strong early clinical data. Pro forma liquidity exceeds $340 million post-offering, supporting operations through 2028 and enabling strategic optionality without near-term capital needs.
Read full article